Tumor necrosis factor (TNF-α) and lymphotoxin (TNF-β)

doi:10.1016/0952-7915(92)90084-R

Current Opinion in Immunology

Volume 4, Issue 3, June 1992, Pages 327-332

https://doi.org/10.1016/0952-7915(92)90084-R Get rights and content

Abstract

Distinctions between tumor necrosis factor, TNF-α, and lymphotoxin, TNF-β, have previously been based on the differences between their protein sequences, biological activity, and molecular regulation. In the past year, elucidation of the molecular nature of the two molecules and the interactions with common receptors has emphasized their similarities, although profound differences continue to emerge with regard to their mode of production, transcription rates, mRNA half-lives, and the importance of various DNA regulatory sequences. A role for both TNF-α and TNF-β has recently been suggested with regard to disease, particularly multiple sclerosis. The past year has also seen the description of an extensive microsatellite polymorphic system which should provide a more definitive understanding of the association of the TNF locus with disease.

References (40)

M. Kriegler et al.
A Novel Form of TNF/Cachectin is a Cell Surface Cytotoxic Transmembrane Protein: Ramifications for the Complex Physiology of TNF
Cell
(1988)
H. Loetscher et al.
Molecular Cloning and Expression of the Human 55 kDa Tumor Necrosis Factor Receptor
Cell
(1990)
M. Lewis et al.
Cloning and Expression of cDNAs for Two Distinct Murine Tumor Necrosis Factor Receptors Demonstrate One Receptor is Species Specific
C.A. Smith et al.
T2 Open Reading Frame for the Shope Fibroma Virus Encodes a Soluble Form of the TNF Receptor
Biochem Biophys Res Comm
(1991)
A.F. Goldfeld et al.
Human Tumor Necrosis Factor α Gene Regulation in Phorbol Ester Stimulated T and B Cell Lines
J Exp Med
(1991)
N.L. Paul et al.
Lymphotoxin Activation by Human T-cell Leukemia Virus Type I-infected Cell Lines: Role for NK-χB
J Virol
(1990)
M.K. Sharief et al.
Association Between Tumor Necrosis Factor-α and Disease Progression in Multiple Sclerosis
New Engl J Med
(1991)
J. Partanen et al.
Low Degree of DNA Polymorphism in the HLA-linked Lymphotoxin (Tumor Necrosis Factor-β) Gene
Scand J Immunol
(1988)
E.Y. Jones et al.
Structure of Tumor Necrosis Factor
Nature
(1989)
J.L. Browning et al.
Lymphotoxin and an Associated 33 kDa Glycoprotein are Expressed on the Surface of an Activated T Cell Hybridoma
J Immunol
(1991)

M.J. Androlewicz et al.

Lymphotoxin is Expressed as a Heterodimeric Complex with a Distinct 33 KD Glycoprotein on the Surface of an Activated Human T Cell Hybridoma

J Biol Chem

(1991)

C.R. Goh et al.

Aspartic Acid 50 and Tyrosine 108 are Essential for Receptor Binding and Cytotoxic Activity of Tumor Necrosis Factor Beta (Lymphotoxin)

Prot Eng

(1991)

H.J. Schoenfeld et al.

Efficient Purification of Recombinant Human Tumor Necrosis Factor β from Escherichia coli Yields a Biologically Active Protein with a Trimeric Structure that Binds to both Tumor Necrosis Factor Receptors

J Biol Chem

(1991)

Z. Van Ostade et al.

Localization of the Active Site of Human Tumor Necrosis Factor (hTNF) by Mutational Analysis

EMBO J

(1991)

T.J. Schall et al.

Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor

Cell

(1990)

K. Barrett et al.

Cloning, Expression and Crosslinking Analysis of the Murine p55 Tumor Necrosis Factor Receptor

Eur J Immunol

(1991)

R.G. Goodwin et al.

Molecular Cloning and Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor

Mol Cell Biol

(1991)

H-P. Hohmann et al.

Expression of the Types A and B Tumor Necrosis Factor (TNF) Receptors is Independently Regulated, and Both Receptors Mediate Mediarte Activation of Regulated, and Both Receptors Mediate Activation of the Transcription Factor, NF-χB

J Biol Chem

(1991)

J. Derre et al.

The Gene for Type 1 Tumor Necrosis Factor Receptor (TNF-R1) is Localized on Band 12p13

Hum Genet

(1991)

H. Loetscher et al.

Recombinant 55-kDa Tumor Necrosis Factor (TNF) Receptor

J Biol Chem

(1991)

Cited by (153)

Systems pharmacology dissection of action mechanisms of Dipsaci Radix for osteoporosis
2019, Life Sciences
Osteoporosis (OP) is a systemic metabolic bone disease characterized by bone mass decrease and microstructural degradation, which may increase the risk of bone fracture and leading to high morbidity. Dipsaci Radix (DR), one typical traditional Chinese medicine (TCM), which has been applied in the treatment of OP with good therapeutic effects and few side effects. However, the underlying molecular mechanisms of DR to treat OP have not been fully elucidated. In this study, we aim to dissect the molecular mechanism of DR in the treatment of OP.
A systems pharmacology approach was employed to comprehensively dissect the action mechanisms of DR for the treatment of OP.
10 compounds were screened out as the potential active ingredients with excellent biological activity based on in silico ADME (absorption, distribution, metabolism and excretion) prediction model. Then, 36 key protein targets of 6 compounds were identified by systems drug targeting model (SysDT) and they were involved in several biological processes, such as osteoclast differentiation, osteoblast differentiation and anti-inflammation. The target-pathway network indicated that targets are mainly mapped in multiple signaling pathways, i.e., MAPK, Tumor necrosis factor α (TNF-α), NF-κb and Toll-like receptor pathways. The in vitro results indicated that the compounds ursolic acid and beta-sitosterol effectively inhibited the osteoclast differentiation.
These results systematically dissected that DR exhibits the therapeutic effects of OP by the regulation of immune system-related pathways, which provide novel perspective to drug development of OP.
Meningococcal PorB induces a robust and diverse antigen specific T cell response as a vaccine adjuvant
2018, Vaccine
Vaccines formulated with adjuvant have been effective against numerous infectious diseases, almost always due to induction of functional antibodies that recognizes the pathogen of interest. There is an unmet clinical need for vaccine adjuvants that induce T cells responses to potentially enhance protection against malignancies and intracellular pathogens, where a humoral response, alone, may not be adequate for protection. In this study, we demonstrate that a TLR2 ligand-based adjuvant, meningococcal PorB, has broad immunostimulatory activity with the ability to induce a robust and diverse vaccine antigen specific T cell response. We demonstrate that a vaccine formulated with PorB admixed with ovalbumin induces a wide variety of antigen specific antibody subclasses and effector molecules (MIG, MCP-1, IP-10, MIP-1α, KC & IL-2) with known roles for inducing T cell responses, along with elevated levels of Th1 and Th2 type cytokines upon antigen stimulation. We confirmed production of these cytokines by examining the antigen-specific T cells induced by PorB in vivo. After two immunizations with vaccine formulated with PorB/OVA, antigen-specific CD4 and CD8 T cells were significantly increased in numbers and produced IL-4 or IFN-γ upon ex vivo antigen re-stimulation. Finally, in a Listeria mouse infection model, vaccine formulated with PorB significantly reduced the bacterial burden upon a low dose infection and increased survival upon a high dose infection with recombinant Listeria monocytogenes engineered to express OVA (rLmOVA), a pathogen that requires OVA-antigen specific cytotoxic CD8 T cells for clearance. In summary, PorB is able to induce antigen specific broad B and T cell responses, illustrating its potential as a potent and new vaccine adjuvant.
Immunomodulatory effects of M2000 (β-D-Mannuronic acid) on TNF-α, IL-17 and FOXP3 gene expression in patients with inflammatory bowel disease
2017, International Immunopharmacology
Citation Excerpt :
It's orchestrating role in colonic inflammation established the basis of anti-TNF-α antibody therapy in IBD. TNF-α produced by activated mononuclear cells is a potent pro-inflammatory and immunoregulatory cytokine [10]. It was named TNF-α at the beginning because of its cytotoxic and anti-tumor activities [11].
Inflammatory bowel diseases (IBD) are immune-mediated disorders that result from an aberrant immunological response to the gut luminal antigen in genetically susceptible patients. IBD is categorized into two serotype, Crohn's diseases (CD) and ulcerative colitis (UC), both subtype are important cause of gastrointestinal diseases. The increasing rate of hospitalization, with the high economic burden experienced by the IBD patients, calls for more concerted research efforts to design a potent and affordable treatment option for the treatment of IBD.
This research was designed to test the efficacy and potency of β-D Mannuronic acid (M2000) and assess if it could serve as a better therapeutic option in the treatment of IBD.
Ten (10)ml of blood was aseptically collected into an EDTA container, from 24 IBD patients and 24 normal healthy controls. PBMC was isolated and stimulated with 1 μg/ml of LPS in cell culture plate and incubated for 4 h. The cells were later treated with 10 μg/ml and 50 μg/ml of β-D Mannuronic acid (M2000) and incubated for 24 h at 37 °C under 5% CO2 and 100% humidity. The RNA extractions, cDNA synthesis, and QRT-PCR were performed.
Our findings showed a significant down-regulation of TNF-α and IL-17 gene expression, while the expression of FOXP3 gene was significantly up-regulated.
This result has indicated that β-D Mannuronic acid (M2000) have immunoregulatory and anti-inflammatory effects on these cytokines that are pivotal in the pathogenesis of IBD.
Lymphotoxin organizes contributions to host defense and metabolic illness from innate lymphoid cells
2014, Cytokine and Growth Factor Reviews
Citation Excerpt :
Lymphotoxin α (LTα) and lymphotoxin β (LTβ) are Tumor Necrosis Factor Superfamily (TNFSF) members TNFSF1 and TNFSF3, and these two species form a heterotrimer with distinct molecular function to that of TNF. LTα and TNF are archetypical members of the TNFSF and obtained their distinct monikers by the observation that these molecules could induce death in fibrosarcoma cells and were secreted by lymphocytes and monocytes respectively [1,2]. Due to the structural homology between LTα and TNF [3,4], it was originally unappreciated that there was a distinct signaling pathway directed completely by LTα [5–7].
The lymphotoxin (LT)-pathway is a unique constituent branch of the Tumor Necrosis Superfamily (TNFSF). Use of LT is a critical mechanism by which fetal innate lymphoid cells regulate lymphoid organogenesis. Within recent years, adult innate lymphoid cells have been discovered to utilize this same pathway to regulate IL-22 and IL-23 production for host defense. Notably, genetic studies have linked polymorphisms in the genes encoding LTα to several phenotypes contributing to metabolic syndrome. The role of the LT-pathway may lay the foundation for a bridge between host immune response, microbiota, and metabolic syndrome. The contribution of the LT-pathway to innate lymphoid cell function and metabolic syndrome will be visited in this review.
Increased liver apoptosis and tumor necrosis factor expression in Atlantic bluefin tuna (Thunnus thynnus) reared in the northern Adriatic Sea
2013, Marine Pollution Bulletin
Citation Excerpt :
Among them there are tumor necrosis factor (TNF) ligand super family proteins, which are known as pluripotent mediators of inflammatory and immune defence mechanisms (García-Castillo et al., 2002; Goetz et al., 2004; Kadowaki et al., 2009) and are responsible for a wide range of cellular responses such as phagocytosis, chemotaxis, and the production of effector molecules, reactive oxygen and nitrogen intermediates (Cunha et al., 1994; Kisich et al., 2002; Ma, 2001). In mammals, two TNF isoforms are known since early 1990s, respectively called TNFα and TNFβ (Limphotoxyn) (Ruddle, 1992), and both of them are expressed by macrophages, monocytes, neutrophils, natural killer (NK) cells and T cells (Goetz et al., 2004; Praveen et al., 2006). TNF-α is also present in fish and is believed to play a role in preventing infectious diseases as in mammals.
The Atlantic bluefin tuna Thunnus thynnus (ABFT) is intensely fished in the Mediterranean Sea to supply a prosperous capture-based mariculture industry. Liver apoptotic structures and tumor necrosis factor (TNF) gene expression were determined in: wild ABFT caught in the eastern Atlantic; juvenile ABFT reared in the central Adriatic Sea; juvenile ABFT reared in the northern Adriatic Sea; adult ABFT reared in the western Mediterranean. The highest density of liver apoptotic structures was found in the juveniles from the northern Adriatic. Two partial TNF cDNAs (TNF1 and TNF2) were cloned and sequenced. TNF1 gene expression was higher in juveniles than in adults. The highest expression of TNF2 was found in the juveniles from the northern Adriatic. These findings might be related to the juvenile exposure to environmental pollutants.
Hydrophobic cavity in C-terminus is essential for hTNF-α trimer conformation
2012, Biochimie
A variety of tumour necrosis factor α (TNF-α) derivatives have been bioengineered to improve antitumour activity and reduce toxicity. The expression of TNF-α in Escherichia coli usually yields a mixture of homotrimers and monomers; however, only the trimer shows antitumour activity. TNF-αD10, a bioengineered hTNF-α derivative, demonstrated 10-fold higher cytotoxicity against tumour cells compared to hTNF-α, but the trimer to monomer ratio was 58:42. In the present study, we investigated the structural differences between the trimer and the monomer of TNF-αD10. We found that the chemical shifts of the C-terminal Trp¹¹⁴ in the trimer were significantly different from those in the monomer and that the replacement of Trp¹¹⁴ with different amino acids remarkably reduced the trimer production. Further analysis of the publicly available X-ray crystallographic data for trimeric and monomeric hTNF-α revealed that the conformation of the U-shaped region formed by the fragment Cys¹⁰¹–Trp¹¹⁴ was different between the two forms: a hydrophilic cavity in the monomer and a hydrophobic cavity in the trimer. These findings suggested the potential approaches of molecular and structural modification for future improvement of hTNF-α trimer production.

View all citing articles on Scopus

View full text

Tumor necrosis factor (TNF-α) and lymphotoxin (TNF-β)

Abstract

Cell

Cell

Biochem Biophys Res Comm

J Exp Med

J Virol

New Engl J Med

Scand J Immunol

Structure of Tumor Necrosis Factor

Nature

Lymphotoxin and an Associated 33 kDa Glycoprotein are Expressed on the Surface of an Activated T Cell Hybridoma

J Immunol

Lymphotoxin is Expressed as a Heterodimeric Complex with a Distinct 33 KD Glycoprotein on the Surface of an Activated Human T Cell Hybridoma

J Biol Chem

Aspartic Acid 50 and Tyrosine 108 are Essential for Receptor Binding and Cytotoxic Activity of Tumor Necrosis Factor Beta (Lymphotoxin)

Prot Eng

Efficient Purification of Recombinant Human Tumor Necrosis Factor β from Escherichia coli Yields a Biologically Active Protein with a Trimeric Structure that Binds to both Tumor Necrosis Factor Receptors

J Biol Chem

Localization of the Active Site of Human Tumor Necrosis Factor (hTNF) by Mutational Analysis

EMBO J

Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor

Cell

Cloning, Expression and Crosslinking Analysis of the Murine p55 Tumor Necrosis Factor Receptor

Eur J Immunol

Molecular Cloning and Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor

Mol Cell Biol

Expression of the Types A and B Tumor Necrosis Factor (TNF) Receptors is Independently Regulated, and Both Receptors Mediate Mediarte Activation of Regulated, and Both Receptors Mediate Activation of the Transcription Factor, NF-χB

J Biol Chem

The Gene for Type 1 Tumor Necrosis Factor Receptor (TNF-R1) is Localized on Band 12p13

Hum Genet

Recombinant 55-kDa Tumor Necrosis Factor (TNF) Receptor

J Biol Chem